Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-22, Stock:ABBV, The news for the past five days is as follows:
2018-02-14: NEWS1: AbbVie Appears Ready to Start a New Advance at Any Time.NEWS2: Lilly's Taltz Positive in Phase III Label Expansion Study.NEWS3: Lilly's Taltz Positive in Phase III Label Expansion Study.NEWS4: MTUM, BA, ABBV, C: ETF Inflow Alert.NEWS5: MTUM, BA, ABBV, C: ETF Inflow Alert.NEWS6: Inside Pfizer’s Inflammation and Immunology Portfolio Performances in 2017.NEWS7: Lilly&apos;s Taltz Positive in Phase III Label Expansion Study.NEWS8: 3 Top Stocks You Can Buy and Hold for the Next Decade.NEWS9: 3 Top Stocks You Can Buy and Hold for the Next Decade.NEWS10: Bristol-Myers Squibb’s Orencia and Other Brands in 4Q17.NEWS11: 3 Top Stocks You Can Buy and Hold for the Next Decade.NEWS12: 3 Dividend Stocks for In-the-Know Investors.NEWS13: 3 Dividend Stocks for In-the-Know Investors.NEWS14: 3 Dividend Stocks for In-the-Know Investors.NEWS15: Is Now a Good Time to Buy AbbVie?.NEWS16: Is Now a Good Time to Buy AbbVie?.NEWS17: Is Now a Good Time to Buy AbbVie?.
2018-02-15: NEWS1: AbbVie Stock Rises After Increasing Dividend By 35%.NEWS2: AbbVie to buy back $10 billion of shares, raises dividend.NEWS3: 5 Cheap Dividend Stocks With Growing Payouts.NEWS4: 6 Healthcare Stocks We Think Deserve Gold Medals (Hint: One's a Marijuana Stock).NEWS5: 6 Healthcare Stocks We Think Deserve Gold Medals (Hint: One's a Marijuana Stock).NEWS6: AbbVie to buy back $10 billion of shares, raises dividend.NEWS7: AbbVie to buy back $10 billion of shares, raises dividend.NEWS8: AbbVie stock rises after dividend boosted 35%, new $10 billion buyback program.NEWS9: AbbVie Increases Dividend and Announces New Stock Repurchase Program.NEWS10: How Analysts View Bristol-Myers Squibb after Its 4Q17 Earnings.NEWS11: [$$] AbbVie shares the wealth with dividend boost, $10bn in buybacks.
2018-02-16: NEWS1: Health Care Sector Update for 02/16/2018: ABBV,APRI,UTHR,PCRX.NEWS2: Health Care Sector Update for 02/16/2018: ABBV,APRI,UTHR,PCRX.NEWS3: AbbVie Inc. -- Moody's says AbbVie's shareholder payouts are credit negative.NEWS4: How Cosentyx Resolves Enthesitis in Psoriatic Arthritis Patients.NEWS5: AbbVie Inc (ABBV) Files 10-K for the Fiscal Year Ended on December 31, 2017.NEWS6: Novartis’s Cosentyx May Emerge as a Leading Psoriasis Drug.NEWS7: Novartis’s Cosentyx Emerged as Multi-Blockbuster Therapy in 2017.NEWS8: Top-Rated Stocks: Zoetis Sees Composite Rating Climb To 97.NEWS9: Top-Rated Stocks: Zoetis Sees Composite Rating Climb To 97.NEWS10: Stocks To Watch: Bristol-Myers Squibb Sees RS Rating Jump To 83.NEWS11: Stocks To Watch: Bristol-Myers Squibb Sees RS Rating Jump To 83.NEWS12: AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks.NEWS13: Coca-Cola earnings show the beverage business—not bottling—is booming.NEWS14: AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan.NEWS15: AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan.NEWS16: Merck’s Immunology and Cardiovascular Products in 4Q17.NEWS17: AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan.NEWS18: Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America?.NEWS19: Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America?.NEWS20: Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America?.NEWS21: 5 Cheap Dividend Stocks with Growing Payouts.NEWS22: 5 Cheap Dividend Stocks with Growing Payouts.NEWS23: AbbVie Stock Rises After Increasing Dividend By 35%.NEWS24: AbbVie Stock Rises After Increasing Dividend By 35%.
2018-02-20: NEWS1: Why Noble Energy, Voyager Therapeutics, and NXP Semiconductors Jumped Today.NEWS2: Why Noble Energy, Voyager Therapeutics, and NXP Semiconductors Jumped Today.NEWS3: 3 More Reasons to Buy AbbVie Stock.NEWS4: 3 More Reasons to Buy AbbVie Stock.NEWS5: Close Update: Late Sell-Off Triggered by Upcoming FOMC Minutes, Breach in Tech Supports.NEWS6: Close Update: Late Sell-Off Triggered by Upcoming FOMC Minutes, Breach in Tech Supports.NEWS7: Health Care Sector Update for 02/20/2018: ANAB,VYGR,ABBV,AIMT,CELG.NEWS8: Health Care Sector Update for 02/20/2018: ANAB,VYGR,ABBV,AIMT,CELG.NEWS9: VYGR Soars On Alzheimer's Deal, RARX Up 21% In 5 Days, ATXI Catches Eyes.NEWS10: VYGR Soars On Alzheimer's Deal, RARX Up 21% In 5 Days, ATXI Catches Eyes.NEWS11: 3 More Reasons to Buy AbbVie Stock.NEWS12: Health Care Sector Update for 02/20/2018: VYGR,ABBV,AIMT,CELG.NEWS13: Health Care Sector Update for 02/20/2018: VYGR,ABBV,AIMT,CELG.NEWS14: Cambridge's Voyager, AbbVie to pursue Alzheimer's gene therapy under $69M deal.NEWS15: Novartis Psoriasis Drug Cosentyx Positive in SCALP Study.NEWS16: Novartis Psoriasis Drug Cosentyx Positive in SCALP Study.NEWS17: Netflix Leads 5 Top Stocks Booming After Standing Ground In Correction.NEWS18: Health Care Sector Update for 02/20/2018: AIMT, CELG, LLY, VYGR, ABBV.NEWS19: Health Care Sector Update for 02/20/2018: AIMT, CELG, LLY, VYGR, ABBV.NEWS20: Trial Tests FTC's Power to Referee Drugmakers' Fight Against Generics.NEWS21: AbbVie and Voyager Therapeutics Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer's Disease and Other Tau-Related Neurodegenerative Diseases.NEWS22: Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases.
2018-02-21: NEWS1: How An AbbVie Deal Sent This Biotech Stock To A 2-Year High.NEWS2: ANTH Awaits RESULT In Mar., HAIR Grows, NITE Shines, TRXC On Must-watch List.NEWS3: ANTH Awaits RESULT In Mar., HAIR Grows, NITE Shines, TRXC On Must-watch List.NEWS4: Here’s What The AbbVie and Voyager Therapeutics Deal Really Means.NEWS5: Can Johnson & Johnson Replace Remicade for $100 Million Upfront?.NEWS6: Can Johnson & Johnson Replace Remicade for $100 Million Upfront?.NEWS7: AbbVie, Neurocrine shares rise after positive results for uterine fibroids drug.NEWS8: AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids.NEWS9: Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA® (Adalimumab) to manage their disease.NEWS10: AbbVie Reports Positive Topline Results From Phase 3 Elagolix Study.NEWS11: AbbVie Reports Positive Topline Results From Phase 3 Elagolix Study.NEWS12: Trial Tests FTC’s Power to Referee Drug Makers’ Fight Against Generics.

Answer: Decrease